Genome Analysis Across Populations in Inflammatory Bowel Disease
Observational · No treatment assigned · 1 site · Mount Sinai Hospital, Canada
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: Ulcerative Colitis, Healthy and Crohn Disease. This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Age range not stated in the record
- Any sex
- Healthy volunteers accepted
Some of the main requirements, copied from the record:
- Subjects: diagnosed with Inflammatory Bowel Disease (Crohn's disease, ulcerative colitis, IBD-undetermined)
- Available medical records to confirm IBD diagnosis (Crohn's disease, Ulcerative colitis, IBD undetermined (IBD-U))
- Healthy controls: no personal history of IBD, no family history of IBD, no history of unexplained chronic diarrhea/blood in stool/anemia/abdominal pain/weight loss
- Any age
There are also 1 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 150 participants are expected to take part.
- The study has 2 groups.
- Start date: 2022-05-01.
- Main results expected around 2027-05 (estimate from the record).
- 1 study site listed (1 marked recruiting) in Canada.
Groups in this study
- IBD Subjects
- Controls
Main thing being measured
- Genomics studies across populations (2022-2027)
In the researchers’ words
Objective: To use clinical, genetic and genome analysis to better understand and define the genetic and environmental factors that contribute to IBD within affected populations.
This summary was written automatically from the official record using fixed templates (no AI), so it only says what the record says, and may leave things out.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | Ulcerative Colitis; Healthy; Crohn Disease; Inflammatory Bowel Diseases |
| Lead sponsor | Mount Sinai Hospital, Canada |
| Collaborators | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Enrollment | 150 (estimated) |
| Start date | 2022-05-01 |
| Primary completion (est.) | 2027-05 |
| First posted | 2023-09-18 |
| Last updated | 2026-10-09 |
| Official title | Genome Analysis Across Populations in Inflammatory Bowel Disease |
| ClinicalTrials.gov ID | NCT06042387 |
Interventions
- Blood or saliva sample collection (Genetic)
Blood or saliva sample \& clinical data collection
Full eligibility criteria (from the record)
Inclusion Criteria: * Subjects: diagnosed with Inflammatory Bowel Disease (Crohn's disease, ulcerative colitis, IBD-undetermined) * Available medical records to confirm IBD diagnosis (Crohn's disease, Ulcerative colitis, IBD undetermined (IBD-U)) * Healthy controls: no personal history of IBD, no family history of IBD, no history of unexplained chronic diarrhea/blood in stool/anemia/abdominal pain/weight loss * Any age Exclusion Criteria: \- Subjects with other gastrointestinal conditions not meeting the above IBD or Healthy Control criteria
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| Sinai Health System | Toronto, Ontario | Canada | Recruiting |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.